Dublin-listed pharmaceutical services company Open Orphan said its subsidiary hVivo has signed an £8.1 million (€9.5 million) asthma contract with a major pharmaceutical firm to test an inhaled human rhinovirus antiviral product.
Around 5.4 million people in the UK are currently receiving treatment for asthma. Illnesses such as the common cold, which can be caused by the human rhinovirus, can make symptoms worse.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).